Quick Answer
Definium Therapeutics, Inc. reported Cash and Equivalents of $257.84 million for fiscal year 2025.
Definium Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $257.84M | -5.8% |
| 2024 | $273.74M | +174.6% |
| 2023 | $99.70M | -29.9% |
| 2022 | $142.14M | +6.4% |
| 2021 | $133.54M | +66.7% |
| 2020 | $80.09M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $19.96M | -93.2% | -40.2% |
| June 30, 2025 | $33.39M | -86.3% | -59.7% |
| March 31, 2025 | $82.85M | -67.2% | -69.7% |
| December 31, 2024 | $273.74M | +174.6% | -7.3% |
| September 30, 2024 | $295.28M | +150.9% | +21.5% |
| June 30, 2024 | $243.13M | +108.0% | -3.6% |
| March 31, 2024 | $252.33M | +95.0% | +153.1% |
| December 31, 2023 | $99.70M | -29.9% | -15.3% |
- Definium Therapeutics, Inc. showed a decrease of -5.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Definium Therapeutics, Inc.’s cash and equivalents has grown by 221.9% (from $80.09 million to $257.84 million).
- The most recent figure is from Definium Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: